LOCAMETZ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Locametz, and what generic alternatives are available?
Locametz is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-four patent family members in fifteen countries.
The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
DrugPatentWatch® Generic Entry Outlook for Locametz
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for LOCAMETZ
International Patents: | 34 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for LOCAMETZ |
What excipients (inactive ingredients) are in LOCAMETZ? | LOCAMETZ excipients list |
DailyMed Link: | LOCAMETZ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LOCAMETZ
Generic Entry Date for LOCAMETZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for LOCAMETZ
LOCAMETZ is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LOCAMETZ is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting LOCAMETZ
PSMA binding ligand-linker conjugates and methods for using
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
FDA Regulatory Exclusivity protecting LOCAMETZ
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LOCAMETZ
When does loss-of-exclusivity occur for LOCAMETZ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08289108
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 96627
Estimated Expiration: ⤷ Try a Trial
China
Patent: 2014956
Estimated Expiration: ⤷ Try a Trial
Patent: 4873982
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 87965
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 87965
Estimated Expiration: ⤷ Try a Trial
Patent: 88086
Estimated Expiration: ⤷ Try a Trial
Patent: 56403
Estimated Expiration: ⤷ Try a Trial
Patent: 31380
Estimated Expiration: ⤷ Try a Trial
Patent: 38298
Estimated Expiration: ⤷ Try a Trial
Patent: 58347
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 12588
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 47200
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 3998
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 02237
Estimated Expiration: ⤷ Try a Trial
Patent: 96479
Estimated Expiration: ⤷ Try a Trial
Patent: 25690
Estimated Expiration: ⤷ Try a Trial
Patent: 38118
Estimated Expiration: ⤷ Try a Trial
Patent: 79355
Estimated Expiration: ⤷ Try a Trial
Patent: 10536790
Estimated Expiration: ⤷ Try a Trial
Patent: 14221779
Estimated Expiration: ⤷ Try a Trial
Patent: 16153410
Estimated Expiration: ⤷ Try a Trial
Patent: 18058864
Estimated Expiration: ⤷ Try a Trial
Patent: 18150350
Estimated Expiration: ⤷ Try a Trial
Patent: 20073472
Estimated Expiration: ⤷ Try a Trial
Patent: 21075561
Estimated Expiration: ⤷ Try a Trial
Patent: 22110118
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 3931
Estimated Expiration: ⤷ Try a Trial
Patent: 0085
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 87965
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 87965
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 87965
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 68224
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LOCAMETZ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 104873982 | PSMA binding ligand-linker conjugates and methods for using | ⤷ Try a Trial |
Japan | 2022110118 | PSMA結合性リガンド-リンカー結合体及び使用方法 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2009026177 | ⤷ Try a Trial | |
Japan | 6596479 | ⤷ Try a Trial | |
European Patent Office | 3656403 | PROCÉDÉS DE PRÉPARATION DE CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA (PREPARATION PROCESS OF PSMA BINDING LIGAND-LINKER CONJUGATES) | ⤷ Try a Trial |
Spain | 2768224 | ⤷ Try a Trial | |
Hong Kong | 1212588 | 結合配體-接頭綴合物及其使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PSMA -) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |